
Phil Dormitzer, who left Pfizer to become GSK’s global vaccine research chief, will need to move beyond the Covid shot and deliver some breakthroughs to challenge his former employer and other rivals. The pressure is on as the British company prepares to spin off its consumer unit this month.
“The focus on vaccines is huge right now,” Dormitzer said in an interview from outside Boston, where he’s based. “After the separation of the consumer-health business, it will be an even more prominent part of the overall organization.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app